{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T21:40:46Z","timestamp":1769722846075,"version":"3.49.0"},"reference-count":161,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1053\/j.semnuclmed.2010.08.005","type":"journal-article","created":{"date-parts":[[2010,11,26]],"date-time":"2010-11-26T09:13:13Z","timestamp":1290762793000},"page":"29-44","source":"Crossref","is-referenced-by-count":77,"title":["PET\/CT Imaging and Radioimmunotherapy of Prostate Cancer"],"prefix":"10.1053","volume":"41","author":[{"given":"Kirsten","family":"Bouchelouche","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott T.","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley J.","family":"Goldsmith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baris","family":"Turkbey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Capala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Choyke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2010.08.005_bib1","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S0140-6736(08)60729-1","article-title":"Prostate cancer","volume":"371","author":"Damber","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib3","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJMe0901166","article-title":"Screening for prostate cancer\u2014the controversy that refuses to die","volume":"360","author":"Barry","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11934-010-0110-z","article-title":"Active surveillance for prostate cancer: a review","volume":"11","author":"Klotz","year":"2010","journal-title":"Curr Urol Rep"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib5","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s11934-010-0102-z","article-title":"Technological advances in radiation therapy for prostate cancer","volume":"11","author":"Choi","year":"2010","journal-title":"Curr Urol Rep"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib6","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points","volume":"14","author":"Tannock","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib7","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1200\/JCO.1999.17.8.2506","article-title":"Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study","volume":"17","author":"Kantoff","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib8","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib9","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11934-010-0104-x","article-title":"Emerging therapies in castrate-resistant prostate cancer","volume":"11","author":"Zarour","year":"2010","journal-title":"Curr Urol Rep"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib11","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/CCO.0b013e32832a1868","article-title":"Emerging therapies in castrate-resistant prostate cancer","volume":"21","author":"Lassi","year":"2009","journal-title":"Curr Opin Oncol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib12","first-page":"297","article-title":"Radioimmunotherapy of prostate cancer","volume":"48","author":"Smith-Jones","year":"2004","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib13","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/CCO.0b013e3283373d5c","article-title":"\u201cImage and treat\u201d: An individualized approach to urological tumors","volume":"22","author":"Bouchelouche","year":"2010","journal-title":"Curr Opin Oncol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib14","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/cncr.24795","article-title":"Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer","volume":"116","author":"Tagawa","year":"2010","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib15","first-page":"55","article-title":"Prostate-specific membrane antigen-a target for imaging and therapy with radionuclides","volume":"9","author":"Bouchelouche","year":"2010","journal-title":"Discov Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib16","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2214\/AJR.09.2527","article-title":"Imaging localized prostate cancer: current approaches and new developments","volume":"192","author":"Turkbey","year":"2009","journal-title":"AJR Am J Roentgenol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib17","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2214\/AJR.09.2579","article-title":"Challenges in clinical prostate cancer: role of imaging","volume":"192","author":"Kelloff","year":"2009","journal-title":"AJR Am J Roentgenol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/CCO.0b013e32832d56e4","article-title":"Positron emission tomography\/computed tomography and radioimmunotherapy of prostate cancer","volume":"21","author":"Bouchelouche","year":"2009","journal-title":"Curr Opin Oncol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/CCO.0b013e3280ad439b","article-title":"Imaging of prostate cancer","volume":"19","author":"Oehr","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrurol.2009.27","article-title":"Imaging techniques for prostate cancer: implications for focal therapy","volume":"6","author":"Turkbey","year":"2009","journal-title":"Nat Rev Urol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib21","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.eururo.2007.01.061","article-title":"Molecular positron emission tomography and PET\/CT imaging in urological malignancies","volume":"51","author":"Powles","year":"2007","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.semnuclmed.2005.09.001","article-title":"Nuclear medicine studies of the prostate, testes, and bladder","volume":"36","author":"Jana","year":"2006","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.juro.2007.08.176","article-title":"Positron emission tomography and positron emission tomography\/computerized tomography of urological malignancies: an update review","volume":"179","author":"Bouchelouche","year":"2008","journal-title":"J Urol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib24","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S0022-5347(01)66366-3","article-title":"Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose","volume":"155","author":"Effert","year":"1996","journal-title":"J Urol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib25","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0969-8051(96)00044-3","article-title":"Detection of bony metastases of androgen-independent prostate cancer by PET-FDG","volume":"23","author":"Yeh","year":"1996","journal-title":"Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib26","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1148\/radiology.199.3.8638000","article-title":"Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-d-glucose","volume":"199","author":"Shreve","year":"1996","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000019923","article-title":"Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy","volume":"36","author":"Hofer","year":"1999","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib28","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/jjco\/29.12.623","article-title":"The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer","volume":"29","author":"Oyama","year":"1999","journal-title":"Jpn J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib29","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0090-4295(00)00896-7","article-title":"Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer","volume":"57","author":"Liu","year":"2001","journal-title":"Urology"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib30","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1097\/00006231-200109000-00004","article-title":"FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation","volume":"22","author":"Oyama","year":"2001","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1095-0397(01)00065-6","article-title":"Prognostic value of 2-deoxy-2-[F-18]fluoro-d-glucose positron emission tomography imaging for patients with prostate cancer","volume":"4","author":"Oyama","year":"2002","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib32","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0090-4295(02)01509-1","article-title":"Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer","volume":"59","author":"Morris","year":"2002","journal-title":"Urology"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000070141","article-title":"Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer","volume":"70","author":"Chang","year":"2003","journal-title":"Urol Int"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib34","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1158\/1078-0432.CCR-05-0249","article-title":"Two-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy","volume":"11","author":"Schoder","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1095-0397(99)00015-1","article-title":"Differential metabolism and pharmacokinetics of L-[1-(11) C]-methionine and 2-[(18)F] fluoro-2-deoxy-d-glucose (FDG) in androgen independent prostate cancer","volume":"2","author":"Macapinlac","year":"1999","journal-title":"Clin Positron Imaging"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib36","first-page":"46","article-title":"Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer","volume":"43","author":"Nunez","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib37","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00259-002-1104-y","article-title":"Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients","volume":"30","author":"Fricke","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib38","first-page":"181","article-title":"11C-acetate PET imaging of prostate cancer","volume":"43","author":"Oyama","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib39","first-page":"549","article-title":"11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse","volume":"44","author":"Oyama","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib40","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/01.ju.0000056901.95996.43","article-title":"Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography","volume":"169","author":"Picchio","year":"2003","journal-title":"J Urol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib41","first-page":"366","article-title":"Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer","volume":"45","author":"Larson","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib42","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/jmri.22157","article-title":"Preoperative detection of prostate cancer: a comparison with 11C-choline PET, 18F-fluorodeoxyglucose PET and MR imaging","volume":"31","author":"Watanabe","year":"2010","journal-title":"J Magn Reson Imaging"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib43","first-page":"1805","article-title":"Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers","volume":"42","author":"DeGrado","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib44","first-page":"990","article-title":"PET imaging of prostate cancer using carbon-11-choline","volume":"39","author":"Hara","year":"1998","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib45","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s002590000309","article-title":"Experience with carbon-11 choline positron emission tomography in prostate carcinoma","volume":"27","author":"Kotzerke","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib46","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0302-2838(02)00129-X","article-title":"Visualization of prostate cancer with 11C-choline positron emission tomography","volume":"42","author":"de Jong","year":"2002","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib47","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0302-2838(03)00207-0","article-title":"11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer","volume":"44","author":"de Jong","year":"2003","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib48","first-page":"331","article-title":"Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET","volume":"44","author":"de Jong","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib49","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00259-003-1377-9","article-title":"Kinetics of [(11)C]choline uptake in prostate cancer: a PET study","volume":"31","author":"Sutinen","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib50","first-page":"1642","article-title":"Detection and localization of prostate cancer: correlation of (11)C-choline PET\/CT with histopathologic step-section analysis","volume":"46","author":"Farsad","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib51","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s00259-004-1755-y","article-title":"Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy","volume":"32","author":"Yamaguchi","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib52","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000083551","article-title":"11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging","volume":"74","author":"Yoshida","year":"2005","journal-title":"Urol Int"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib53","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.juro.2006.04.015","article-title":"11C-choline positron emission tomography\/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy","volume":"176","author":"Martorana","year":"2006","journal-title":"J Urol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib54","first-page":"1249","article-title":"Imaging prostate cancer with 11C-choline PET\/CT","volume":"47","author":"Reske","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib55","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1464-410X.2007.07083.x","article-title":"Evaluation of [11C]-choline positron-emission\/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer","volume":"100","author":"Rinnab","year":"2007","journal-title":"BJU Int"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib56","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/j.1464-410X.2007.06776.x","article-title":"11C-choline positron-emission tomography\/computed tomography and transrectal ultrasonography for staging localized prostate cancer","volume":"99","author":"Rinnab","year":"2007","journal-title":"BJU Int"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib57","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00259-006-0190-7","article-title":"Value of 11C-choline PET and PET\/CT in patients with suspected prostate cancer","volume":"34","author":"Scher","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib58","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1148\/radiol.2443061063","article-title":"Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET\/CT","volume":"244","author":"Testa","year":"2007","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib59","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000144059","article-title":"[11C]Choline PET\/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer","volume":"81","author":"Rinnab","year":"2008","journal-title":"Urol Int"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib60","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.eururo.2008.04.030","article-title":"(11)C-choline positron emission tomography\/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms","volume":"54","author":"Schiavina","year":"2008","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib61","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/RLU.0b013e318184b3a0","article-title":"C-11 choline PET\/CT imaging for differentiating malignant from benign prostate lesions","volume":"33","author":"Li","year":"2008","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib62","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00345-009-0371-7","article-title":"[(11)C]choline PET\/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy","volume":"27","author":"Rinnab","year":"2009","journal-title":"World J Urol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib63","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2967\/jnumed.108.061507","article-title":"Influence of trigger PSA and PSA kinetics on 11C-choline PET\/CT detection rate in patients with biochemical relapse after radical prostatectomy","volume":"50","author":"Castellucci","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib64","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000296298","article-title":"First results of [11C]choline PET\/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy","volume":"84","author":"Winter","year":"2010","journal-title":"Urol Int"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib65","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s12149-010-0390-x","article-title":"Role of 11C-choline PET\/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy","volume":"24","author":"Fuccio","year":"2010","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib66","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1055\/s-0038-1623902","article-title":"Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer","volume":"42","author":"Kotzerke","year":"2003","journal-title":"Nuklearmedizin"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib67","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/01.ju.0000142099.80156.85","article-title":"Prostate cancer localization with 18fluorine fluorocholine positron emission tomography","volume":"173","author":"Kwee","year":"2005","journal-title":"J Urol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib68","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1148\/radiol.2352040494","article-title":"Fluorocholine PET\/CT in patients with prostate cancer: initial experience","volume":"235","author":"Schmid","year":"2005","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib69","first-page":"262","article-title":"Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET","volume":"47","author":"Kwee","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib70","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s00259-006-0150-2","article-title":"[(18)F]fluorocholine PET\/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients","volume":"33","author":"Cimitan","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib71","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1016\/j.juro.2006.07.037","article-title":"Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection","volume":"176","author":"Hacker","year":"2006","journal-title":"J Urol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib72","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11307-005-0023-2","article-title":"Positron emission tomography\/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA <5 ng\/ml?","volume":"8","author":"Heinisch","year":"2006","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib73","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00259-007-0552-9","article-title":"Evaluation of [(18)F]-choline PET\/CT for staging and restaging of prostate cancer","volume":"35","author":"Husarik","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib74","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/s00259-007-0686-9","article-title":"The value of 18F-choline PET\/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer","volume":"35","author":"Igerc","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib75","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2310\/7290.2008.00002","article-title":"Use of step-section histopathology to evaluate 18F-fluorocholine PET sextant localization of prostate cancer","volume":"7","author":"Kwee","year":"2008","journal-title":"Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib76","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ejca.2009.11.008","article-title":"[F(18)]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: preliminary results from a prospective histology-based study","volume":"46","author":"Steuber","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib77","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1148\/radiol.09090413","article-title":"18F choline PET\/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients","volume":"254","author":"Beheshti","year":"2010","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib78","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s11307-009-0217-0","article-title":"The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT","volume":"11","author":"Beheshti","year":"2009","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib79","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1464-410X.2009.09191.x","article-title":"[(18)F]-fluorocholine positron-emission\/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study","volume":"106","author":"Poulsen","year":"2010","journal-title":"BJU Int"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib80","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/j.1464-410X.2007.06772.x","article-title":"18F-choline and\/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng\/mL) after radical prostatectomy","volume":"99","author":"Vees","year":"2007","journal-title":"BJU Int"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib81","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s00259-008-0788-z","article-title":"Detection of bone metastases in patients with prostate cancer by (18)F fluorocholine and (18)F fluoride PET-CT: a comparative study","volume":"35","author":"Beheshti","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib82","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.2967\/jnumed.108.050658","article-title":"Novel tracers and their development for the imaging of metastatic prostate cancer","volume":"49","author":"Apolo","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib83","first-page":"420","article-title":"18F-fluoroacetate: a potential acetate analog for prostate tumor imaging\u2014in vivo evaluation of 18F-fluoroacetate versus 11C-acetate","volume":"48","author":"Ponde","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib84","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1007\/s00259-002-0885-3","article-title":"Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer","volume":"29","author":"Kato","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib85","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1007\/s00259-002-0882-6","article-title":"Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer","volume":"29","author":"Kotzerke","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib86","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.urology.2005.11.044","article-title":"Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy","volume":"67","author":"Sandblom","year":"2006","journal-title":"Urology"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib87","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1200\/JCO.2005.03.5279","article-title":"11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer","volume":"24","author":"Wachter","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib88","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00259-006-0163-x","article-title":"(11)C-acetate PET in the early evaluation of prostate cancer recurrence","volume":"34","author":"Albrecht","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib89","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.radonc.2009.08.010","article-title":"Carbon-11 acetate PET\/CT based dose escalated IMRT in prostate cancer","volume":"93","author":"Seppala","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib90","first-page":"46","article-title":"A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer","volume":"48","author":"Oka","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib91","first-page":"56","article-title":"Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET\/CT in prostate carcinoma","volume":"48","author":"Schuster","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib92","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/01.ju.0000148326.71981.44","article-title":"Detection of prostate cancer with 11C-methionine positron emission tomography","volume":"173","author":"Toth","year":"2005","journal-title":"J Urol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib93","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s00259-005-1764-5","article-title":"Positron tomographic assessment of androgen receptors in prostatic carcinoma","volume":"32","author":"Dehdashti","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib94","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1053\/j.semnuclmed.2007.07.002","article-title":"18F-fluoride positron emission tomography and positron emission tomography\/computed tomography","volume":"37","author":"Even-Sapir","year":"2007","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib95","first-page":"287","article-title":"The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET\/CT","volume":"47","author":"Even-Sapir","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib96","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1007\/s00259-007-0658-0","article-title":"18F FBEM-Z-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography","volume":"35","author":"Kramer-Marek","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib97","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2967\/jnumed.108.057695","article-title":"Changes in HER2 expression in breast cancer xenografts after therapy Can Be quantified using PET and 18F-labeled Affibody molecules","volume":"50","author":"Kramer-Marek","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib98","doi-asserted-by":"crossref","first-page":"892","DOI":"10.2967\/jnumed.109.073239","article-title":"Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled Affibody molecules","volume":"51","author":"Baum","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib99","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.urology.2007.10.022","article-title":"Trends in Gleason score: concordance between biopsy and prostatectomy over 15 years","volume":"72","author":"Rajinikanth","year":"2008","journal-title":"Urology"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib100","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.rcl.2006.10.008","article-title":"Imaging of prostate cancer","volume":"45","author":"Akin","year":"2007","journal-title":"Radiol Clin North Am"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib101","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1056\/NEJMoa022749","article-title":"Noninvasive detection of clinically occult lymph-node metastases in prostate cancer","volume":"348","author":"Harisinghani","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib102","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00259-006-0163-x","article-title":"(11)C-acetate PET in the early evaluation of prostate cancer recurrence","volume":"34","author":"Albrecht","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib103","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/cncr.24896","article-title":"Pathogenesis of osteoblastic bone metastases from prostate cancer","volume":"116","author":"Ibrahim","year":"2010","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib104","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s00259-009-1334-3","article-title":"The added value of multislice SPECT\/CT in patients with equivocal bony metastasis from carcinoma of the prostate","volume":"37","author":"Helyar","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib105","first-page":"1623","article-title":"Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18-F pet","volume":"40","author":"Schirrmeister","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib106","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2967\/jnumed.106.037200","article-title":"Skeletal PET with 18F-fluoride: applying new technology to an old tracer","volume":"49","author":"Grant","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib107","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/cncr.10304","article-title":"Rationales, evidence, and design considerations for fractionated radioimmunotherapy","volume":"94","author":"Denardo","year":"2002","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib108","first-page":"538","article-title":"Single-dose versus fractionated radioimmunotherapy: model comparisons for uniform tumor dosimetry","volume":"41","author":"O'Donoghue","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib109","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/cncr.10295","article-title":"Model prediction of treatment planning for dose-fractionated radioimmunotherapy","volume":"94","author":"Shen","year":"2002","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib110","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/10849780152389401","article-title":"Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy","volume":"16","author":"Kroger","year":"2001","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib111","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/0969-8051(93)90025-P","article-title":"Fractionated intravenous administration of 90Y-labeled B72.3 GYK-DTPA immunoconjugate in beagle dogs","volume":"20","author":"Vriesendorp","year":"1993","journal-title":"Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib112","first-page":"5881s","article-title":"Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49","volume":"55","author":"Buchsbaum","year":"1995","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib113","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/cbr.1998.13.239","article-title":"Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody","volume":"13","author":"Denardo","year":"1998","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib114","first-page":"1615","article-title":"Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy","volume":"59","author":"Steffens","year":"1999","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib115","first-page":"4003s","article-title":"Change in tumor-absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients","volume":"9","author":"Hindorf","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib116","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/pros.10029","article-title":"Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6","volume":"50","author":"O'Donnell","year":"2002","journal-title":"Prostate"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib117","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1158\/1078-0432.CCR-05-0211","volume":"11","author":"Richman","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib118","first-page":"716","article-title":"Enhanced efficacy of 90Y-radiolabeled anti-lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model","volume":"47","author":"Kelly","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib119","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1200\/JCO.2009.21.9170","article-title":"American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy","volume":"27","author":"Allegra","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib120","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","article-title":"Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience","volume":"96","author":"Kaminski","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib121","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib122","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/blood-2003-01-0287","article-title":"A phase 2 trial of CHOP chemotherapy followed by tositumomab\/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group protocol S9911","volume":"102","author":"Press","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib123","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib124","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1200\/JCO.2005.14.803","article-title":"Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma","volume":"23","author":"Leonard","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib125","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","article-title":"Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group protocol S9911","volume":"24","author":"Press","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib126","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/cbr.2006.21.81","article-title":"Editorial: what ails solid tumor radioimmunotherapy?","volume":"21","author":"Divgi","year":"2006","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib127","first-page":"1902","article-title":"Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides","volume":"36","author":"O'Donoghue","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib128","first-page":"1017","article-title":"Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49","volume":"35","author":"Meredith","year":"1994","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib129","first-page":"1561","article-title":"Radioimmunotherapy with (111)In\/(90)Y-2IT-BAD-m170 for metastatic prostate cancer","volume":"7","author":"O'Donnell","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib130","doi-asserted-by":"crossref","first-page":"5604s","DOI":"10.1158\/1078-0432.CCR-07-1071","article-title":"Radioimmunotherapy with alpha-particle emitting 213Bi\u2013C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy","volume":"13","author":"Kelly","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib131","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2967\/jnumed.108.055608","article-title":"In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin\/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice","volume":"50","author":"Schneider","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib132","first-page":"1289","article-title":"Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody","volume":"2","author":"Deb","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib133","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/cbr.1999.14.99","article-title":"A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy","volume":"14","author":"Kahn","year":"1999","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib134","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2004.09.154","article-title":"Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer","volume":"22","author":"Milowsky","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib135","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1200\/JCO.2005.05.160","article-title":"Phase I trial of 177lutetium-labeled J591; A monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer","volume":"23","author":"Bander","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib136","first-page":"927","article-title":"Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients","volume":"7","author":"Horoszewicz","year":"1987","journal-title":"Anticancer Res"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib137","first-page":"227","article-title":"Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen","volume":"53","author":"Israeli","year":"1993","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib138","first-page":"1807","article-title":"Expression of the prostate-specific membrane antigen","volume":"54","author":"Israeli","year":"1994","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib139","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ijc.2910620511","article-title":"Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids","volume":"62","author":"Troyer","year":"1995","journal-title":"Int J Cancer"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib140","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/(SICI)1097-0045(20000501)43:2<150::AID-PROS10>3.0.CO;2-B","article-title":"A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine","volume":"43","author":"Sokoloff","year":"2000","journal-title":"Prostate"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib141","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S","article-title":"Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases","volume":"82","author":"Bostwick","year":"1998","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib142","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0022-5347(01)63239-7","article-title":"111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy; The ProstaScint Study Group","volume":"159","author":"Kahn","year":"1998","journal-title":"J Urol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib143","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1200\/JCO.1998.16.1.284","article-title":"Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy","volume":"16","author":"Kahn","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib144","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/(SICI)1097-0045(19970301)30:4<232::AID-PROS2>3.0.CO;2-N","article-title":"Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line","volume":"30","author":"Troyer","year":"1997","journal-title":"Prostate"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib145","first-page":"3629","article-title":"Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium","volume":"57","author":"Liu","year":"1997","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib146","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1053\/suro.2002.36250","article-title":"The utility of monoclonal antibodies in the imaging of prostate cancer","volume":"20","author":"Yao","year":"2002","journal-title":"Semin Urol Oncol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib147","first-page":"4055","article-title":"Constitutive and antibody-induced internalization of prostate-specific membrane antigen","volume":"58","author":"Liu","year":"1998","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib148","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1097\/01.ju.0000091655.77601.0c","article-title":"Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen","volume":"170","author":"Bander","year":"2003","journal-title":"J Urol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib149","doi-asserted-by":"crossref","first-page":"284s","DOI":"10.1200\/jco.2008.26.15_suppl.5140","article-title":"Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients with metastatic castrate-resistent prostate cancer","volume":"26","author":"Tagawa","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib150","series-title":"Phase I trial of fractionated-dose 177lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monocloncal antibody J591 (177Lu-J591) in patients (pts) with metastatic castration-resistent prostate cancer (metCRPC)","author":"Tagawa","year":"2010"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib151","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1002\/1097-0142(19930601)71:11<3774::AID-CNCR2820711147>3.0.CO;2-0","article-title":"Investigation of taxol as a potential radiation sensitizer","volume":"71","author":"Choy","year":"1993","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib152","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0360-3016(92)90888-O","article-title":"Taxol: a novel radiation sensitizer","volume":"22","author":"Tishler","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib153","first-page":"1720","article-title":"Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing v-79 and HeLa cells","volume":"54","author":"Hennequin","year":"1994","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib154","series-title":"Phase I dose escalation study of docetaxel\/prednisone and fractionated 177Lu-J591 for metastatic castrate resistant prostate cancer (metCRPC)","author":"Beltran","year":"2010"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib155","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/S0022-5347(05)67511-8","article-title":"Prostate specific antigen only progression of prostate cancer","volume":"163","author":"Moul","year":"2000","journal-title":"J Urol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib156","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.2004.07.099","article-title":"Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group","volume":"22","author":"Scher","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib157","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1097\/01.ju.0000173911.82467.f9","article-title":"Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates","volume":"174","author":"Pazona","year":"2005","journal-title":"J Urol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib158","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.juro.2006.04.083","article-title":"Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system","volume":"176","author":"Buskirk","year":"2006","journal-title":"J Urol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib159","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jama.291.11.1325","article-title":"Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy","volume":"291","author":"Stephenson","year":"2004","journal-title":"JAMA"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib160","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1097\/01.ju.0000145262.34748.2b","article-title":"Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy","volume":"172","author":"Ward","year":"2004","journal-title":"J Urol"},{"key":"10.1053\/j.semnuclmed.2010.08.005_bib161","series-title":"A randomized phase II trial of 177Lu radiolabeled monocloncal antibody J591 (177Lu-J591) and ketoconazole in patients (pts) with high-risk castrate biochemically relapsed prostate cancer (PC) after local therapy","author":"Tagawa","year":"2010"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299810000784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299810000784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T03:30:02Z","timestamp":1592105402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299810000784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":161,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0001299810000784"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2010.08.005","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}